Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glivec plus hydroxyurea vs hydroxyurea alone in temozolomide-resistant progressive glioblastoma
2004-004063-29Phase 3Terminated
- Sponsor
- Novartis
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of imatinib in glioblastoma (GBM) (2 arms), sponsored by Novartis. Primary endpoint: Progression-free survival (PFS) rate during entire study. Started Nov 2004; status: terminated.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2004-004063-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004063-29.